Results 11 to 20 of about 180,190 (229)

Recurrence of neovascular age-related macular degeneration after cessation of treat and extend regimen [PDF]

Scientific Reports, 2022
The appropriate timing of treatment cessation after treat and extend (TAE) regimen for age-related macular degeneration has not been established. This study aimed to investigate the incidence and risk factors of recurrence after cessation of the TAE ...
Yuki Hirata, Akio Oishi, Yuki Maekawa, Eiko Tsuiki, Akira Machida, Junko Kurihara, Takashi Kitaoka   +6 more
doaj   +4 more sources

Recurrence of neovascular age-related macular degeneration after discontinuation of modified treat and extend treatment [PDF]

Scientific Reports
We evaluated the incidence and risk factors for recurrence in patients with neovascular age-related macular degeneration (nAMD) who discontinued anti-vascular endothelial growth factor (VEGF) therapy under a modified treat-and-extend (TAE) protocol.
Junwoo Lee, Jaehwan Choi, Seung-Young Yu, Kiyoung Kim   +3 more
doaj   +4 more sources

Randomized Trial of Treat-and-Extend Intravitreal Aflibercept for Radiation Retinopathy: 1-Year Outcomes. [PDF]

Invest Ophthalmol Vis Sci, 2023
Radiation retinopathy (RR)-related macular edema commonly causes poor visual acuity outcomes in patients previously treated with ocular radiation therapy. Current treatments are not US Food and Drug Administration (FDA)-approved and prior studies have variable outcomes.
Trejo Corona S, Villanueva Boone C, Ali AM, Moore C, Brown A, Munoz J, Aaberg T, Schefler AC, ARRT Study Group.   +8 more
europepmc   +3 more sources

Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients [PDF]

Vision, 2019
Treat and extend (T&E) is a standard treatment regimen for treating neovascular age-related macular degeneration (nAMD) with anti-vascular endothelial growth factors (anti-VEGFs), but the treatment intervals attained are not well documented.
Adrian Skelly, Vladimir Bezlyak, Gerald Liew, Elisabeth Kap, Alexandros Sagkriotis   +4 more
doaj   +3 more sources

Faricimab treat-and-extend approach for neovascular age-related macular degeneration: insights from real-world clinical practice [PDF]

International Journal of Retina and Vitreous
Purpose To evaluate the clinical outcomes of the switch to faricimab in a treat-and-extend (T&E) regimen patients with neovascular age-related macular degeneration (nAMD).
Jorge Ruiz-Medrano, Iulia Pana, María García-Zamora, Ignacio Flores-Moreno, Mariluz Puertas, José Mª Ruiz-Moreno   +5 more
doaj   +2 more sources

A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result [PDF]

Pharmaceuticals, 2023
We aimed to investigate whether a treat-and-extend regimen of intravitreal brolucizumab (6.0 mg/0.05 mL) is effective for eyes with exudative age-related macular degeneration (AMD) refractory to aflibercept for 12 months.
Wataru Kikushima, Yoichi Sakurada, Yoshiko Fukuda, Mio Matsubara, Yumi Kotoda, Atsushi Sugiyama, Kenji Kashiwagi   +6 more
doaj   +2 more sources

Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice [PDF]

Ophthalmology and Therapy
Introduction Anti-vascular endothelial growth factor (VEGF) is generally given using pro re nata or “treat-and-extend” (T&E) regimens for neovascular age-related macular degeneration (nAMD).
Eloi Debourdeau, Helene Beylerian, Vuong Nguyen, Daniel Barthelmes, Mark Gillies, Pierre Henry Gabrielle, Stela Vujosevic, Louise Otoole, Martin Puzo, Catherine Creuzot-Garcher, Benjamin Wolff, Vincent Daien, The Fight Retinal Blindness! Study Group   +12 more
doaj   +2 more sources

Flexible Loading Phase Treat-and-Extend Regimen with Faricimab for Neovascular Age-Related Macular Degeneration: A Real-World Study [PDF]

Biomedicines
Background/Objectives: We aimed to evaluate the efficacy of a flexible loading-phase treat-and-extend regimen using faricimab, in which the number of loading-phase intravitreal injections was tailored to individual disease activity.
Akira Machida, Junko Kurihara, Yuki Hirata, Eriko Machida, Ryuya Murakami, Akari Oka, Ai Yoneda, Eiko Tsuiki, Akio Oishi   +8 more
doaj   +2 more sources

Efficacy and safety of treat-and-extend intravitreal brolucizumab in naive and switched patients with macular neovascularization: one-year follow-up study [PDF]

BMC Ophthalmology
Background to analyze, at one year, the efficacy and safety of treat-and-extend (T&E) intravitreal (IV) Brolucizumab in patients affected by macular neovascularization (MNV).
Francesco Faraldi, Carlo Alessandro Lavia, Marco Nassisi, Raphael Kilian, Clara Rizzo, Maria Cristina Savastano, Stanislao Rizzo, Fabrizio Giansanti, Daniela Bacherini   +8 more
doaj   +2 more sources

A Randomized, Controlled Trial of Treat-and-Extend vs. Pro Re Nata Regimen for Neovascular Age-Related Macular Degeneration [PDF]

Frontiers in Medicine, 2022
PurposeTo compare the efficacy and safety of conbercept using a treat-and-extend (T&E) regimen vs. a pro re nata (PRN) regimen in Chinese patients with neovascular age-related macular degeneration (nAMD).MethodsThis was a randomized, multicenter, non-
Huixun Jia, Huixun Jia, Huixun Jia, Huixun Jia, Bing Lu, Bing Lu, Bing Lu, Yuanzhi Yuan, Fei Yuan, Lei Li, Yanping Song, Ao Rong, Minwen Zhou, Minwen Zhou, Minwen Zhou, Fenghua Wang, Fenghua Wang, Fenghua Wang, Fenghua Wang, Xiaodong Sun, Xiaodong Sun, Xiaodong Sun, Xiaodong Sun   +22 more
doaj   +2 more sources